Gary R. Hudes

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Gary R. Hudes, Michael A. Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 3.6K citations

Medicine, Oncology, Chemotherapy +10

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski et al. · JAMA · 2006 · 1.2K citations

Medicine, Oncology, Pharmacology +17

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 984 citations

Medicine, Oncology, Genitourinary Oncology +16

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 943 citations · Full text

Pharmacy, Oncology, Pharmacology +16